Insulet is a high-quality compounder where a temporary execution issue is masking strong underlying fundamentals. Type 2 diabetes represents a major untapped market for the company and GLP-1 adoption potentially will expand rather than cannibalize the opportunity for Insulet’s Omnipod insulin delivery system. The stock’s valuation offers asymmetric upside, with a potential appreciation of more than 30% requiring only a modest re-rating to return to a level that is still well below historical multiples. Wall Street has handed long-term investors a rare mispricing of Insulet shares. The insulin pump maker is trading at its lowest valuation multiple in a decade. It’s the result of a combination of a single-quarter operational miss layered on top of an already over-discounted secular narrative and it’s a setup long-term investors search for: a fixable issue obscuring a durable, multiyear growth story. Overblown fears surrounding GLP-1 weight loss drugs were already pressuring Insulet’s stock when an onboarding stumble in the U.S. Type 2 diabetes market triggered a sell-off. Although second-quarter results were an across-the-board beat on key headline numbers, Insulet shares fell roughly 20% on Aug. 5 as the company slashed its full-year revenue forecast. The stock, while on the mend, has recovered less than half of its loss since then. The post-earnings drawdown was out of proportion to a guidance trim that was concentrated in one distribution channel. A few sell-side analysts reacted by downgrading the stock in the days that followed. Both the sell-off and downgrades are an overreaction to a fixable execution issue. The positive view is intentionally contrarian. Insulet doesn’t have a demand problem. Last quarter’s revenue grew 23.5% year-over-year, exceeding consensus expectations. It hasn’t seen market share loss, pricing pressure, or weakening end-market demand. Instead, during a 90-day patient onboarding process in the U.S., Insulet successfully signed up new Type 2 diabetes patients, but too many stopped using the Omnipod insulin pump within their first three months of treatment. This is a retention problem Insulet believes it can fix by improving early patient support and follow-up. Insulet’s international growth has been accelerating, with revenue rising between 30% and 32%, and full-year earnings per share growth anticipated to jump more than 30% from a year earlier. A modest re-rating back toward a still-conservative 28x multiple yields a $196 price target, well short of Insulet’s own historical range, and more than 30% above where the stock closed Aug. 31. In addition, GLP-1 weight loss drugs are expanding Insulet’s future patient pool, not shrinking it as some investors fear. Treatments like Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound don’t replace the insulin pumps Insulet manufactures. Instead, GLP-1 drugs bring more patients with Type 2 diabetes into active treatment, and a large share will need insulin and a delivery device like the Omnipod. Real-world data show GLP-1 use roughly doubles the rate at which Type 2 patients start insulin therapy. If investors see this play out, this overhang on the stock may ease, further aiding valuation. Insulet’s competitive moat Insulet’s Omnipod is a tubeless wearable insulin pump that automatically delivers insulin to people with diabetes. The device’s lack of tubing is a plus because it reduces the risk it will snag on objects, a problem its tethered competitors face. The design is one of Omnipod’s competitive advantages. It also is available through pharmacies rather than the more cumbersome medical equipment channel and it works with leading glucose monitors such as Dexcom’s G7 and Abbott’s FreeStyle Libre 3 Plus, allowing patients to choose their preferred glucose sensor rather than being locked into a particular brand. The company operates a “razor-and-blade” recurring revenue model. Patients purchase 3-day wearable, disposable Omnipods, generating predictable, high-margin cash flow. This occurs with minimal working capital drag, since fulfillment runs through pre-established pharmacy networks rather than capital-intensive durable equipment logistics. Insulet reaches more than 90% of U.S. pharmacies, allowing patients to access Omnipod for roughly $30 a month without being locked into long-term medical-equipment contracts. This makes adoption easier than with many traditional insulin pumps. The U.S. generates about 70% to 75% of revenue, but international markets are becoming increasingly important as Insulet expands across Europe. The company’s balance sheet supports its growth story. The company employs minimal leverage and gross margins of about 68% to 70% are expanding as automated manufacturing lines in Malaysia and the U.S. scale efficiency. A reality check of the latest results Insulet’s second-quarter results were strong on the surface. Revenue of $801.7 million was ahead of the $787 million Wall Street expected, while adjusted earnings of $1.66 a share beat estimates by more than 15%. Operating margins expanded by 140 basis points, and the number of U.S. doctors prescribing Omnipod grew 27% — good evidence that demand remains healthy. The hiccup was in the fast-growing U.S. Type 2 diabetes business. Insulet has been successful at getting more Type 2 patients to start Omnipod — more than 40% of new U.S. starts come from this group, but too many were dropping off during their first 90 days. In other words, the problem wasn’t convincing doctors or patients to try Omnipod, it was doing enough to help these newer, often first-time pump users make the transition and stick with it. In the second-quarter conference call, CEO Ashley McEvoy acknowledged the company should have identified the drop-off sooner. Insulet is responding with more patient support, greater involvement from primary care physicians and sales incentives that reward 90-day retention rather than simply signing up new users. But the slower ramp-up in users prompted Insulet to lower its forecast for U.S. Omnipod growth to a range of 17% to 19% from between 20% and 22%, bringing expected companywide revenue growth down to between 20% and 22% from roughly 23%. Importantly, the weakness was quite localized. Strong European demand, including the launch in Spain, led management to raise its international Omnipod growth forecast to a range of 30% to 32% from a prior range of 26% to 28%, while its full-year adjusted earnings growth guidance increased to at least 30% from at least 25%. Investors nevertheless punished the stock, sending it to a 52-week intraday low of $126.40. Several Wall Street firms subsequently downgraded Insulet, including Wells Fargo, JP Morgan, Leerink and BTIG. BTIG analyst Marie Thibault, who downgraded Insulet to neutral from buy, said the report “left us with too many questions.” Shares have fallen 48% year to date. Unlocking the Type 2 diabetes market Investors still price the stock as a Type 1 diabetes story, severely underestimating its runway with Type 2 diabetes patients. When the Food and Drug Administration approved the Omnipod 5 for this group in September 2024, Insulet estimated its total addressable market expanded by 6 million people living in the U.S. with insulin-requiring Type 2 diabetes. Since more than 40% of new U.S. starts in the second quarter were Type 2 patients, the evidence of the potential unlock is real, even if the onboarding process needs work. “There’s a significant unmet need in this community,” McEvoy said on the earnings call earlier this month. “We have really strong science, and [American Diabetes Association] guidelines are on our side. We do have synergy and learning from 25 years serving the Type 1 community. And as we stand here in August, we have tens of thousands of Type 2ers who are using Pod and getting fantastic results.” That said, the CEO acknowledged that there are key differences between the two groups. Type 2 diabetes patients tend to be older, have other comorbidities and may be on Medicare or Medicaid rather than private insurance. As part of its effort to boost retention, it is scaling up some pilot programs that provide proactive support during the “early moments of truth” such as the first time a patient needs to change a Pod or refill a prescription. It also expects the increased deployment of its Omnipod Discover customer data platform to help patients see the benefits of therapy and stay engaged. “We do have some strong early proof points that give us confidence in the actions that we’re taking to have an impact on the important metrics that we need to drive,” Eric Benjamin, chief operating officer, said on the call. The third quarter will provide an important early test of these fixes. Investors should watch 90-day patient retention closely. Management has set a lower bar so an upside surprise could provide an early and credible signal of progress. Another potential catalyst is the broader rollout of Abbott’s FreeStyle Libre 3 Plus . While older Omnipods could be used alongside a Libre glucose monitoring system, the new integrations allow the Omnipod 5 to receive glucose levels and automatically adjust insulin every five minutes. Finally, management’s formal 2027 outlook, expected in the fourth quarter, should help investors look past the guidance reset and refocus on the longer-term trajectory. A confident multiyear growth outlook, particularly alongside improving Type 2 retention, could go a long way toward restoring confidence. Competition is heating up as both Tandem Diabetes Care and Medtronic are pursuing the same Type 2 opportunity. Insulet, however, enters the fight with some meaningful advantages that should be difficult to replicate. A less controllable risk is reimbursement. Omnipod’s attractive economics and ease of access depend partly on Medicare, Medicaid, and commercial insurers continuing to provide favorable coverage for insulin-pump therapy. Any meaningful tightening of coverage or reimbursement could make Omnipod more expensive for patients and reduce the size of its opportunity, regardless of how well Insulet executes. Debunking the GLP-1 threat The concern that GLP-1 medications would decimate the insulin delivery market was largely a market myth driven by investor panic. In late 2023, the exploding popularity of these drugs caused shares of medical device companies like Insulet to plummet, fueled by the narrative that GLP-1s would eliminate the need for insulin. This panic conflated the patient bases of Type 1 and Type 2 diabetes. In reality, GLP-1s do not cure or alter the absolute need for insulin in Type 1 diabetics, who have a lifetime dependence on automated insulin delivery systems and make up Insulet’s core target market. Furthermore, actual financial performance has debunked this “demand cliff” thesis. Instead of facing structural decline, Insulet continued to log massive growth. Analysts note that GLP-1s can act as a gateway, extending the time Type 2 patients spend in specialized clinical care before eventually transitioning onto insulin pumps. While Insulet stock may face volatility from unrelated issues, the underlying secular demand for tubeless insulin delivery remains highly resilient against the GLP-1 wave. Valuation Insulet’s stock trades at a ~21x forward P/E, near its all-time valuation floor, well below its historical 10-year range of roughly 40x to 60x, and below the 30x to 40x multiples the market affords high-growth medtech peers despite Insulet’s comparable or superior top-line growth. Applying a conservative 28x forward P/E — which itself is a discount to both the stock’s historical median and to peer multiples — to consensus 12-month forward consensus EPS of $7.00 yields a price target of $196, or more than 30% upside. The conservatism is deliberate: even if the Type 2 onboarding issue takes several quarters to fully resolve, a 28x multiple does not require the market to underwrite a full return to Insulet’s historical 40x–60x range, only a partial re-rating off the stock’s current trough. Insulet combines exclusive product differentiation, massive Type 2 diabetes market expansion, and exceptional recurring revenue economics. With the stock trading at less than half its traditional valuation, the market has priced in something close to a permanent impairment for what looks, on the evidence to date, like a temporary operational issue. Meanwhile, the clinical data undercuts the GLP-1 bear case, and Insulet’s balance sheet and margin profile show no cracks beyond the specific retention metric management flagged. The stock’s valuation gap versus both Insulet’s own history and its peer group appears wide enough to absorb a slower-than-hoped fix without requiring a heroic re-rating. By the time that fog clears — likely as third-quarter retention data or the fourth-quarter long-range forecast reset lands — this entry point will likely be gone. THIS CONTENT IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSTITUTE FINANCIAL, INVESTMENT, TAX OR LEGAL ADVICE OR A RECOMMENDATION TO BUY ANY SECURITY OR OTHER FINANCIAL ASSET. THE CONTENT IS GENERAL IN NATURE AND DOES NOT REFLECT ANY INDIVIDUAL’S UNIQUE PERSONAL CIRCUMSTANCES. THE ABOVE CONTENT MIGHT NOT BE SUITABLE FOR YOUR PARTICULAR CIRCUMSTANCES. BEFORE MAKING ANY FINANCIAL DECISIONS, YOU SHOULD STRONGLY CONSIDER SEEKING ADVICE FROM YOUR OWN FINANCIAL OR INVESTMENT ADVISOR. Click here for the full disclaimer.
